CELLINK launches the BIO CELLX platform, a novel biodispensing tool to automate 3D cell culture
This first-of-its-kind technology aims to provide a simple solution for high throughput model generation
11 Mar 2022
CELLINK, A BICO Company, has launched the BIO CELLX, a novel system that automates 3D cell culture workflows by leveraging pre validated protocols. The BIO CELLX builds upon CELLINK's impressive bioprinting portfolio utilizing proven technologies like the patented Clean Chamber combined with a unique new method for effortless mixing of hydrogels and cells, high precision dispensing, and automatic nozzle priming to create a system for reproducible and high throughput model generation.
By introducing the concept of pre-validated protocols, the BIO CELLX provides cell biologists a solution for the development of 3D models without the need for coding, CAD modeling, or parameter selection and optimization. The BIO CELLX continues to harness the power of bioconvergence through the use of ECM based hydrogels provided by Advanced BioMatrix, another BICO group company.
"This product is an important step in proliferating 3D cell culture and the numerous advantages it can bring to cell biologists. With the BIO CELLX we have developed a solution that effectively empowers researchers to transition to 3D cell culture workflows, providing effective and reproducible models that can truly improve research outcomes," says Johan Norrman, CTO, CELLINK.
"We are thrilled to be bringing the BIO CELLX to the drug discovery market. For the last 5 years we have developed cutting edge bioprinters and have utilized this expertise to develop an automated biodispensing platform solution that makes the power of 3D accessible to all with easy to understand set up and effortless material and cell mixing. We look forward to enabling the pharma industry with technology which we hope will bring meaningful breakthroughs in cancer research and therapy development by providing biomimetic models," added Cecilia Edebo, CEO, CELLINK.
